Its conceivable that the Phase 1B trial currently underway at two clinical centers in the US will continue to utilise the existing delivery method throughout those trials there... and it certainly is looking that way. Meanwhile, the new trial design is expected to be conducted simultaneously here in Australia once the IND is approved. That would be advantageous for an expedited approach, as data is collected for CHM-1101 regardless of the proposed new trial design with the possibility of preliminary Phase 1B data from our US counterparts still on the cards for this year. Is this your interpretation, Reon?
A personalised tool to help users track selected stocks. Delivering real-time notifications on price updates, announcements, and performance stats on each to help make informed investment decisions.
(20min delay)